• Open Access

Asparaginase and MOPP Treatment of Dogs with Lymphoma

Authors


  • The study was performed at the Veterinary Oncology and Hematology Center in Norwalk, CT, The Center for Specialized Veterinary Care in Westbury, NY and the Katonah-Bedford Veterinary Center in Bedford Hills, NY. This study was presented at the 25th Veterinary Cancer Society conference, Huntington Beach, CA, 2005.

Corresponding author: Edwin M. Brodsky, 178 Connecticut Avenue, Norwalk, CT 06854; e-mail: ebrodsky@oncovet.com.

Abstract

Background: Dogs with multicentric lymphoma are treated with various cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy protocols with variable success.

Objectives: To describe the progression-free survival (PFS) time and overall survival time (OST) of dogs with T-cell lymphoma or hypercalcemic lymphoma treated with l-asparaginase and mechlorethamine, vincristine, prednisone, procarbazine (MOPP).

Animals: Fifty dogs with T-cell lymphoma, hypercalcemic lymphoma, or both treated at 3 referral veterinary hospitals.

Methods: Retrospective study. Case were selected based on histologic or cytologic diagnosis of lymphoma; presence of the T-cell phenotype, presence of hypercalcemia or both; and absence of previous chemotherapy. The T-cell phenotype was determined by flow cytometry, immunocytochemistry, immunohistochemistry, or polymerase chain reaction of antigen receptor rearrangement.

Results: The overall response rate was 98% (78% complete response, 20% partial response). The median PFS for the entire study population was 189 days with 25% PFS at 939 days. The median OST for the entire study population was 270 days with 25% surviving 939 days. Twenty percent of the dogs required hospitalization for treatment related complications.

Conclusions and clinical importance: l-Asp/MOPP chemotherapy might result in longer PFS and OST for dogs with multicentric T-cell lymphoma, dogs with hypercalcemic lymphoma or both, than achieved with CHOP.

Ancillary